Cargando…
Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice
Microglial healing peptide 1, “MHP1”, is a newly developed synthetic peptide composed of the DE and a part of the EF loop of the receptor activator of nuclear factor-кB (NFκB) ligand (RANKL). Our previous report demonstrated that MHP1 significantly inhibits Toll-like receptor (TLR) 2- and 4-induced...
Autores principales: | Shimamura, Munehisa, Nakagami, Hironori, Shimizu, Hideo, Wakayama, Kouji, Kawano, Tomohiro, Ikeda, Yuka, Hayashi, Hiroki, Yoshida, Shota, Mochizuki, Hideki, Morishita, Ryuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091369/ https://www.ncbi.nlm.nih.gov/pubmed/30151382 http://dx.doi.org/10.1155/2018/4637084 |
Ejemplares similares
-
Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke
por: Shimamura, Munehisa, et al.
Publicado: (2018) -
Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis
por: Ju, Nan, et al.
Publicado: (2019) -
A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke
por: Kurinami, Hitomi, et al.
Publicado: (2016) -
Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice
por: Ju, Nan, et al.
Publicado: (2022) -
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice
por: Yoshida, Shota, et al.
Publicado: (2020)